Grundlæggende statistik
| LEI | 549300GKR2G40H3QFY57 |
| CIK | 1643918 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Midatech Pharma Plc - ADR
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| May 14, 2026 |
Exhibit 99.3 NOTICE OF ANNUAL GENERAL MEETINGBIODEXA PHARMACEUTICALS PLC(Incorporated and registered in England and Wales with registered no. 09216368)Notice is hereby given that an Annual General Meeting ("AGM") of the members of Biodexa Pharmaceuticals PLC (the "Company") will be held at 1 Caspian Point, Caspian Way, Cardiff, Wales, CF10 4DQ on 17 June 2026 at 11:00 a.m. to consider and, if thou |
|
| May 14, 2026 |
Biodexa Pharmaceuticals PLC Annual Report 2025 Exhibit 99.2Biodexa is a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers Contents Page Strategic Report Strategy 01 Business Model 02 Clinical Stage Assets 02 Chief Executive’s Review 04 Financial Review 06 Stakeholder Engagement/s.172 statement 10 Risk Manageme |
|
| May 14, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2026 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of pri |
|
| May 14, 2026 |
Exhibit 99.5 If you are planning to attend the Annual General Meeting, please tick the following box:>123-0Resolutions (*Special Resolutions)FORM OF PROXYBiodexa Pharmaceuticals PLC(a company incorporated in England and Wales under the Companies Act 2006 with company number 09216368)I?We being (a) member(s) of the Company and entitled to vote at the AnnualGeneral Meeting, hereby appoint(Please onl |
|
| May 14, 2026 |
Exhibit 99.6 ORDINARY RESOLUTIONS SPECIAL RESOLUTIONS FOR AGAINST WITHHELD FOR AGAINST WITHHELD FOR AGAINST WITHHELD Res 1. Res 7. Res 10. Res 2. Res 8. Res 11. Res 3. Res 9. Res 4. Res 5. Res 6. BIODEXA PHARMACEUTICALS PLC TO THE REGISTERED HOLDERS OF AMERICAN DEPOSITARY RECEIPTS ("ADRs") REPRESENTING ORDINARY SHARES OF BIODEXA PHARMACEUTICALS PLC Sign below Date: Please sign this Voting Instruct |
|
| May 14, 2026 |
Exhibit 99.4 t: +44 (0)29 20480180 | www.biodexapharma.com | Registered in England & Wales, No. 09216368 Biodexa Pharmaceuticals PLC 1 Caspian Point Caspian Way Cardiff CF10 4DQ Biodexa Pharmaceuticals PLC (Biodexa or the Company) May 14, 2026 Dear Shareholder, Annual General Meeting Proposals to Reorganize Share Capital Without Affecting Shareholder's Rights or Number of ADSs Outstanding With thi |
|
| May 14, 2026 |
Biodexa issues letter to Shareholders Exhibit 99.1 May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers has today issued the following letter to shareholders explaining the proposals to reorganize the company’s share capital at the forthcoming Annual Gene |
|
| April 2, 2026 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-291598 PROSPECTUS Up to 489,000 American Depositary Shares Representing 48,900,000,000 Ordinary Shares Underlying the Pre-Funded Warrants Up to 6,097,562 American Depositary Shares Representing 609,756,200,000 Ordinary Shares Underlying the Series L Warrants Up to 152,439 American Depositary Shares Representing 15,243,900,000 Ordinary Shares Un |
|
| April 2, 2026 |
Filed Pursuant to Rule 424(b)(3) File No. 333-278040 PROSPECTUS BIODEXA PHARMACEUTICALS PLC 171,700,000 Ordinary Shares Representing 1,717 American Depositary Shares This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of an aggregate of 171,700,000 ordinary shares, nominal value £0.000001 per share, or Ordinary Shares, of Biodexa Pharmaceuticals PLC, o |
|
| April 2, 2026 |
1,701,800,000 Ordinary Shares Representing 17,018 American Depositary Shares Filed Pursuant to Rule 424(b)(3) File No. 333-281489 PROSPECTUS 1,701,800,000 Ordinary Shares Representing 17,018 American Depositary Shares This prospectus relates to the resale from time to time, by the selling shareholders identified in this prospectus, of up to an aggregate of 1,701,800,000 ordinary shares, nominal value £0.000001 per share, or Ordinary Shares, of Biodexa Pharmaceuticals PLC, |
|
| April 2, 2026 |
299,261,540,000 Ordinary Shares Representing 2,992,615 American Depositary Shares Filed Pursuant to Rule 424(b)(3) File No. 333-284350 PROSPECTUS 299,261,540,000 Ordinary Shares Representing 2,992,615 American Depositary Shares This prospectus relates to the potential offer and sale from time to time by C/M Capital Master Fund, LP, or the Selling Shareholder, of up to 299,261,540,000 of our ordinary shares, nominal value £0.000001 per share, or Ordinary Shares, represented by 2 |
|
| April 2, 2026 |
Filed Pursuant to Rule 424(b)(3) File No. 333-272693 PROSPECTUS BIODEXA PHARMACEUTICALS PLC 109,800,000 Ordinary Shares Representing 1,098 American Depositary Shares This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of an aggregate of 109,800,000 ordinary shares, nominal value £0.000001 per share, or Ordinary Shares, of Biodexa Pharmaceuticals PLC, o |
|
| April 2, 2026 |
943,400,000 Ordinary Shares Representing 9,434 American Depositary Shares Filed Pursuant to Rule 424(b)(3) File No. 333-279994 PROSPECTUS 943,400,000 Ordinary Shares Representing 9,434 American Depositary Shares This prospectus relates to the resale from time to time, by the selling shareholders identified in this prospectus, of up to an aggregate of 943,400,000 ordinary shares, nominal value £0.000001 per share, or Ordinary Shares, of Biodexa Pharmaceuticals PLC, or th |
|
| March 30, 2026 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 27, 2026 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 27, 2026 Registration No. |
|
| March 30, 2026 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 27, 2026 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 27, 2026 Registration No. |
|
| March 30, 2026 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 27, 2026 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 27, 2026 Registration No. |
|
| March 30, 2026 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 27, 2026 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 27, 2026 Registration No. |
|
| March 30, 2026 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 27, 2026 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MARCH 27, 2026 Registration No. |
|
| March 30, 2026 |
As filed with the U.S. Securities and Exchange Commission on March 27, 2026. As filed with the U.S. Securities and Exchange Commission on March 27, 2026. Registration No. 333-291598 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 POST-EFFECTIVE AMENDMENT NO. 1 TO REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) England and Wales 2834 Not Applicable (St |
|
| March 27, 2026 |
License and Collaboration Agreement Exhibit 4.21 License and Collaboration Agreement This License and Collaboration Agreement is made and entered into as of February 3, 2026 (the “Effective Date”), between Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), a company incorporated under the laws of Japan with offices at Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-ku, Tokyo 108-8241, Japan, and Biodexa Pharmaceuticals PLC (“Biodexa”), |
|
| March 27, 2026 |
Exhibit 15.1 The Directors Biodexa Pharmaceuticals plc 1 Caspian Point Caspian Way Cardiff Wales CF10 4DQ DDI: +44 (0)20 7516 2200 Email: [email protected] Date: 26 March 2026 Consent of Independent Registered Public Accounting Firm – Exhibit 15.1 Dear Sir / Madam We consent to the inclusion of our audit report dated March 26, 2026 in the Annual Report on Form 20-F on the consolidated financial |
|
| March 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Address |
|
| March 27, 2026 |
Exhibit 13.2 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report on Form 20-F of Biodexa Pharmaceuticals PLC (the “Company”) for the year ended December 31, 2025, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Fiona (Powell) |
|
| March 27, 2026 |
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.2 Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Fiona (Powell) Sharp, certify that: 1. I have reviewed this annual report on Form 20-F of Biodexa Pharmaceuticals PLC (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light o |
|
| March 27, 2026 |
Exhibit 13.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report on Form 20-F of Biodexa Pharmaceuticals PLC (the “Company”) for the year ended December 31, 2025, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Stephen Stamp, |
|
| March 27, 2026 |
Exhibit 15.2 30 Old Bailey London EC4M 7AU Tel: +44 (0)20 7063 4000 forvismazars.com/uk Consent of Independent Registered Public Accounting Firm RE: The Board of Directors of Biodexa Pharmaceuticals PLC, We hereby consent to the incorporation by reference in this Form 20-F (to be filed on or about March 26, 2026) of our audit report dated April 18, 2024 with respect to the consolidated balance she |
|
| March 27, 2026 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934, as amended of Biodexa Pharmaceutucals PLC (“Biodexa,” “we,” “us,” “our” or the “Company”) is a summary of the rights of our issued share capital and certain provisions of our articles of association. Th |
|
| March 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 27, 2026 |
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Stephen Stamp, certify that: 1. I have reviewed this annual report on Form 20-F of Biodexa Pharmaceuticals PLC (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the c |
|
| March 27, 2026 |
Preliminary Results for the Year Ended 31 December 2025 EXHIBIT 99.1 Preliminary Results for the Year Ended 31 December 2025 March 27, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or preventio |
|
| March 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2026 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of p |
|
| March 18, 2026 |
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Exhibit 99.1 March 18, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts (“ADR”) from one (1) ADR representing |
|
| February 4, 2026 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-291598 PROSPECTUS SUPPLEMENT No. 2 (To the Prospectus dated December 17, 2025) BIODEXA PHARMACEUTICALS PLC 157,000 Units, Each Unit Consisting of One American Depositary Share and Two Series L Warrants, Each to Purchase One American Depositary Share, and 2,891,781 Pre-Funded Units, Each Pre-Funded Unit Consisting of One Pre-Funded Warrant to P |
|
| February 4, 2026 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-278040 PROSPECTUS SUPPLEMENT No. 3 (To the Prospectus dated November 21, 2025) BIODEXA PHARMACEUTICALS PLC 171,700,000 Ordinary Shares Representing 1,717 American Depositary Shares This prospectus supplement No. 3 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended |
|
| February 4, 2026 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-272693 PROSPECTUS SUPPLEMENT No. 3 (To the Prospectus dated November 21, 2025) BIODEXA PHARMACEUTICALS PLC 109,800,000 Ordinary Shares Representing 1,098 American Depositary Shares This prospectus supplement No. 3 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended |
|
| February 4, 2026 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 13 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 4,349,000,000 Ordinary Shares Representing 43,490 American Depositary Shares This prospectus supplement No. 13 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| February 4, 2026 |
Exhibit 99.1 February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – February 4, 2025 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of r |
|
| February 4, 2026 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-284350 PROSPECTUS SUPPLEMENT No. 13 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 341,352,000,000 Ordinary Shares Representing 3,413,520 American Depositary Shares This prospectus supplement No. 13 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as ame |
|
| February 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address o |
|
| February 4, 2026 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 13 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 2,486,100,000 Ordinary Shares Representing 24,861 American Depositary Shares This prospectus supplement No. 13 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| January 6, 2026 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-278040 PROSPECTUS SUPPLEMENT No. 2 (To the Prospectus dated November 21, 2025) BIODEXA PHARMACEUTICALS PLC 171,700,000 Ordinary Shares Representing 1,717 American Depositary Shares This prospectus supplement No. 2 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended |
|
| January 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of |
|
| January 6, 2026 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-291598 PROSPECTUS SUPPLEMENT No. 1 (To the Prospectus dated December 17, 2025) BIODEXA PHARMACEUTICALS PLC 157,000 Units, Each Unit Consisting of One American Depositary Share and Two Series L Warrants, Each to Purchase One American Depositary Share, and 2,891,781 Pre-Funded Units, Each Pre-Funded Unit Consisting of One Pre-Funded Warrant to P |
|
| January 6, 2026 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-272693 PROSPECTUS SUPPLEMENT No. 2 (To the Prospectus dated November 21, 2025) BIODEXA PHARMACEUTICALS PLC 109,800,000 Ordinary Shares Representing 1,098 American Depositary Shares This prospectus supplement No. 2 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended |
|
| January 6, 2026 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 12 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 2,486,100,000 Ordinary Shares Representing 24,861 American Depositary Shares This prospectus supplement No. 12 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| January 6, 2026 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 12 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 4,349,000,000 Ordinary Shares Representing 43,490 American Depositary Shares This prospectus supplement No. 9 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| January 6, 2026 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-284350 PROSPECTUS SUPPLEMENT No. 12 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 341,352,000,000 Ordinary Shares Representing 3,413,520 American Depositary Shares This prospectus supplement No. 12 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as ame |
|
| January 5, 2026 |
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary EXHIBIT 99.1 Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products fo |
|
| January 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2026 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Addre |
|
| December 19, 2025 |
Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333-291598 PROSPECTUS 157,000 Units, Each Unit Consisting of One American Depositary Share and Two Series L Warrants, Each to Purchase One American Depositary Share and 2,891,781 Pre-Funded Units, Each Pre-Funded Unit Consisting of One Pre-Funded Warrant to Purchase One American Depositary Share and Two Series L Warrants, Each to Purchase |
|
| December 18, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-272693 PROSPECTUS SUPPLEMENT No. 1 (To the Prospectus dated November 21, 2025) BIODEXA PHARMACEUTICALS PLC 109,800,000 Ordinary Shares Representing 1,098 American Depositary Shares This prospectus supplement No. 1 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended |
|
| December 18, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-278040 PROSPECTUS SUPPLEMENT No. 1 (To the Prospectus dated November 21, 2025) BIODEXA PHARMACEUTICALS PLC 171,700,000 Ordinary Shares Representing 1,717 American Depositary Shares This prospectus supplement No. 1 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended |
|
| December 18, 2025 |
Exhibit 4.1 FORM OF SERIES L WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES BIODEXA PHARMACEUTICALS PLC Warrant Depositary Shares: Issue Date: Initial Exercise Date: THIS SERIES L WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms a |
|
| December 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2025 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Address |
|
| December 18, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 11 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 2,486,100,000 Ordinary Shares Representing 24,861 American Depositary Shares This prospectus supplement No. 8 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| December 18, 2025 |
Biodexa Announces Pricing of $10 Million Public Offering Exhibit 99.1 Biodexa Announces Pricing of $10 Million Public Offering December 18, 2025 Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the pricing of a best efforts public offering of an aggregate of (i) 157,000 u |
|
| December 18, 2025 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT December 17, 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Biodexa Pharmaceuticals PLC, a public limited company organized under the laws of England and Wales (including any successor thereto, the “Company”), hereby agrees to sell up to an aggregate of |
|
| December 18, 2025 |
Exhibit 4.2 FORM OF PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES BIODEXA PHARMACEUTICALS PLC Warrant Depositary Shares: Issue Date: Initial Exercise Date: THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the ter |
|
| December 18, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-284350 PROSPECTUS SUPPLEMENT No. 11 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 341,352,000,000 Ordinary Shares Representing 3,413,520 American Depositary Shares This prospectus supplement No. 8 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amen |
|
| December 18, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 17, 2025, between Biodexa Pharmaceuticals PLC, a public limited company incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “ |
|
| December 18, 2025 |
Exhibit 4.3 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES BIODEXA PHARMACEUTICALS PLC Warrant Depositary Shares: Issue Date: Initial Exercise Date: THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the t |
|
| December 18, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 11 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 4,349,000,000 Ordinary Shares Representing 43,490 American Depositary Shares This prospectus supplement No. 9 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| December 11, 2025 |
Exhibit 10.19 PLACEMENT AGENCY AGREEMENT December [·], 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Biodexa Pharmaceuticals PLC, a public limited company organized under the laws of England and Wales (including any successor thereto, the “Company”), hereby agrees to sell up to an aggregate o |
|
| December 11, 2025 |
Exhibit 4.5 FORM OF SERIES L WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES BIODEXA PHARMACEUTICALS PLC Warrant Depositary Shares: Issue Date: Initial Exercise Date: THIS SERIES L WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms a |
|
| December 11, 2025 |
Exhibit 10.20 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Biodexa Pharmaceuticals PLC, a public limited company incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers |
|
| December 11, 2025 |
As filed with the U.S. Securities and Exchange Commission on December 11, 2025. As filed with the U.S. Securities and Exchange Commission on December 11, 2025. Registration No. 333-291598 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) England and Wales 2834 Not Applicable (State or Other |
|
| December 8, 2025 |
As filed with the U.S. Securities and Exchange Commission on December 8, 2025. As filed with the U.S. Securities and Exchange Commission on December 8, 2025. Registration No. 333-291598 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) England and Wales 2834 Not Applicable (State or Other |
|
| November 24, 2025 |
PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-272693 BIODEXA PHARMACEUTICALS PLC 109,800,000 Ordinary Shares Representing 1,098 American Depositary Shares This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of an aggregate of 109,800,000 ordinary shares, nominal value £0.000001 per share, or Ordinary Shares, of Biodexa Pharmaceutical |
|
| November 24, 2025 |
PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-278040 BIODEXA PHARMACEUTICALS PLC 171,700,000 Ordinary Shares Representing 1,717 American Depositary Shares This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of an aggregate of 171,700,000 ordinary shares, nominal value £0.000001 per share, or Ordinary Shares, of Biodexa Pharmaceutical |
|
| November 17, 2025 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON NOVEMBER 17, 2025 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON NOVEMBER 17, 2025 Registration No. |
|
| November 17, 2025 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON NOVEMBER 17, 2025 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON NOVEMBER 17, 2025 Registration No. |
|
| November 17, 2025 |
As filed with the U.S. Securities and Exchange Commission on November 17, 2025. As filed with the U.S. Securities and Exchange Commission on November 17, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) England and Wales 2834 Not Applicable (State or Other Jurisdiction of Incorpor |
|
| November 17, 2025 |
Exhibit 4.6 FORM OF PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES BIODEXA PHARMACEUTICALS PLC Warrant Depositary Shares: Issue Date: Initial Exercise Date: THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the ter |
|
| November 17, 2025 |
Exhibit 10.19 PLACEMENT AGENCY AGREEMENT [·], 2025 Maxim Group LLC 300 Park Avenue, 16th Floor New York, NY 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”), Biodexa Pharmaceuticals PLC, a public limited company organized under the laws of England and Wales (including any successor thereto, the “Company”), hereby agrees to sell up to an aggregate of $[●]of |
|
| November 17, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-1 Biodexa Pharmaceuticals PLC Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Units, each consisting of one American Depositary Share ("ADS") and one Series L Warrant to purchase one ADS (1) Other $ $ 18,000,000. |
|
| November 17, 2025 |
Exhibit 10.20 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Biodexa Pharmaceuticals PLC, a public limited company incorporated under the laws of England and Wales (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers |
|
| November 17, 2025 |
Exhibit 4.5 FORM OF SERIES L WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES BIODEXA PHARMACEUTICALS PLC Warrant Depositary Shares: Issue Date: Initial Exercise Date: THIS SERIES L WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms a |
|
| November 3, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-284350 PROSPECTUS SUPPLEMENT No. 10 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 341,352,000,000 Ordinary Shares Representing 3,413,520 American Depositary Shares This prospectus supplement No. 10 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as ame |
|
| November 3, 2025 |
Exhibit 99.1 November 3, 2025 Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of d |
|
| November 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address o |
|
| November 3, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 10 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 4,349,000,000 Ordinary Shares Representing 43,490 American Depositary Shares This prospectus supplement No.10 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| November 3, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 10 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 2,486,100,000 Ordinary Shares Representing 24,861 American Depositary Shares This prospectus supplement No. 10 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| September 30, 2025 |
X0101 EFFECT 33 LIVE 2025-09-30 16:00:00 F-3 0001643918 Biodexa Pharmaceuticals Plc 333-290554 |
|
| September 29, 2025 |
Biodexa Pharmaceuticals PLC 1 Caspian Point Caspian Way Cardiff, CF10 4DQ United Kingdom Biodexa Pharmaceuticals PLC 1 Caspian Point Caspian Way Cardiff, CF10 4DQ United Kingdom September 29, 2025 VIA EDGAR U. |
|
| September 29, 2025 |
September 29, 2025 Stephen Stamp Chief Executive Officer Biodexa Pharmaceuticals PLC 1 Caspian Point Caspian Way Cardiff, CF10 4DQ United Kingdom Re: Biodexa Pharmaceuticals PLC Registration Statement on Form F-3 Filed September 26, 2025 File No. |
|
| September 26, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 Biodexa Pharmaceuticals Plc Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Ordinary Shares, nominal value GBP0. |
|
| September 26, 2025 |
As filed with the Securities and Exchange Commission on September 26, 2025 As filed with the Securities and Exchange Commission on September 26, 2025 Registration No. |
|
| September 26, 2025 |
BIODEXA PHARMACEUTICALS PLC [ ] Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Exhibit 4.5 BIODEXA PHARMACEUTICALS PLC Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act Section of of 1939, as Amended Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c) |
|
| September 26, 2025 |
Exhibit 4.6 BIODEXA PHARMACEUTICALS PLC Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) |
|
| September 12, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 9 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 4,349,000,000 Ordinary Shares Representing 43,490 American Depositary Shares This prospectus supplement No. 9 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, e |
|
| September 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address |
|
| September 12, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-284350 PROSPECTUS SUPPLEMENT No. 9 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 341,352,000,000 Ordinary Shares Representing 3,413,520 American Depositary Shares This prospectus supplement No. 9 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amend |
|
| September 12, 2025 |
Exhibit 99.1 September 12, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months end |
|
| September 12, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 9 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 2,486,100,000 Ordinary Shares Representing 24,861 American Depositary Shares This prospectus supplement No. 9 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, e |
|
| August 20, 2025 |
August 20, 2025 Stephen Stamp Chief Executive Officer Biodexa Pharmaceuticals plc 1 Caspian Point Caspian Way Cardiff, CF10 4DQ, United Kingdom Re: Biodexa Pharmaceuticals plc Form 20-F for Fiscal Year Ended December 31, 2024 File No. |
|
| August 19, 2025 |
One Financial Center Boston, MA 02111 617 542 6000 mintz.com August 19, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tracie Mariner and Kevin Vaughn Re: Biodexa Pharmaceuticals plc Form 20-F for Fiscal Year Ended December 31, 2024 File No. 001-37652 Ladies and Gentlemen: We are submitt |
|
| August 18, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 8 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 4,349,000,000 Ordinary Shares Representing 43,490 American Depositary Shares This prospectus supplement No. 8 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, e |
|
| August 18, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 8 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 2,486,100,000 Ordinary Shares Representing 24,861 American Depositary Shares This prospectus supplement No. 8 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, e |
|
| August 18, 2025 |
August 18, 2025 Stephen Stamp Chief Executive Officer Biodexa Pharmaceuticals plc 1 Caspian Point Caspian Way Cardiff, CF10 4DQ, United Kingdom Re: Biodexa Pharmaceuticals plc Form 20-F for Fiscal Year Ended December 31, 2024 File No. |
|
| August 18, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-284350 PROSPECTUS SUPPLEMENT No. 8 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 341,352,000,000 Ordinary Shares Representing 3,413,520 American Depositary Shares This prospectus supplement No. 8 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amend |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Addres |
|
| August 18, 2025 |
EXHIBIT 99.1 Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) August 18, 2025 Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Opportunity to be First Mover in $7.3Bn Addressable Market Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDR |
|
| August 6, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-284350 PROSPECTUS SUPPLEMENT No. 7 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 341,352,000,000 Ordinary Shares Representing 3,413,520 American Depositary Shares This prospectus supplement No. 7 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amend |
|
| August 6, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 7 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 2,486,100,000 Ordinary Shares Representing 24,861 American Depositary Shares This prospectus supplement No. 7 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, e |
|
| August 6, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 7 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 4,349,000,000 Ordinary Shares Representing 43,490 American Depositary Shares This prospectus supplement No. 7 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, e |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Address |
|
| July 31, 2025 |
EXHIBIT 99.1 ADR Ratio Change Effective July 31, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Effective ADSs Outstanding Post Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces the previously announce |
|
| July 18, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 6 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 4,349,102,800 Ordinary Shares Representing 434,901 American Depositary Shares This prospectus supplement No. 6 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| July 18, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 6 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 2,486,190,000 Ordinary Shares Representing 248,619 American Depositary Shares This prospectus supplement No. 6 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| July 18, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-284350 PROSPECTUS SUPPLEMENT No. 6 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 341,352,000,000 Ordinary Shares Representing 34,135,200 American Depositary Shares This prospectus supplement No. 6 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amen |
|
| July 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of pr |
|
| July 15, 2025 |
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Exhibit 99.1 July 15, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts (“ADR”) from one (1) AD |
|
| June 27, 2025 |
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting Exhibit 99.1 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that at its Annual General Meeting held yesterday, all resolutions put to the Company’s shareholde |
|
| June 27, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 5 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 2,486,190,000 Ordinary Shares Representing 248,619 American Depositary Shares This prospectus supplement No. 4 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| June 27, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-284350 PROSPECTUS SUPPLEMENT No. 5 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 341,352,000,000 Ordinary Shares Representing 34,135,200 American Depositary Shares This prospectus supplement No. 4 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amen |
|
| June 27, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 5 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 4,349,102,800 Ordinary Shares Representing 434,901 American Depositary Shares This prospectus supplement No. 3 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of pr |
|
| June 13, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 4 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 2,486,190,000 Ordinary Shares Representing 248,619 American Depositary Shares This prospectus supplement No. 4 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of pr |
|
| June 13, 2025 |
BIODEXA PHARMACEUTICALS PLC (registered number 09216368) ARTICLES OF ASSOCIATION Table of Contents Exhibit 1.1 BIODEXA PHARMACEUTICALS PLC (registered number 09216368) ARTICLES OF ASSOCIATION Table of Contents PRELIMINARY 1 1 DEFINITIONS 1 2 LIABILITY OF MEMBERS 6 3 FORM OF RESOLUTION 6 4 EXCLUSION OF MODEL ARTICLES (AND ANY OTHER PRESCRIBED REGULATIONS) 6 5 REGISTERED OFFICE 6 SHARE CAPITAL 6 6 ALLOTMENT, REDUCTION AND ALTERATION 6 7 SHARE WARRANTS TO BEARER 7 8 COMMISSIONS AND BROKERAGE 8 9 T |
|
| June 13, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-284350 PROSPECTUS SUPPLEMENT No. 4 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 341,352,000,000 Ordinary Shares Representing 34,135,200 American Depositary Shares This prospectus supplement No. 4 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amen |
|
| June 13, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 4 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 4,349,102,800 Ordinary Shares Representing 434,901 American Depositary Shares This prospectus supplement No. 4 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| June 11, 2025 |
EXHIBIT 99.1 Result of General Meeting June 11, 2025 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces, announces that at its General Meeting held earlier today, all four |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Address |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Address |
|
| June 4, 2025 |
Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes EXHIBIT 99.1 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment o |
|
| June 2, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 3 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 4,349,102,800 Ordinary Shares Representing 434,901 American Depositary Shares This prospectus supplement No. 3 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| June 2, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 3 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 2,486,190,000 Ordinary Shares Representing 248,619 American Depositary Shares This prospectus supplement No. 3 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| May 30, 2025 |
EXHIBIT 99.1 Shareholder Update May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced a brief update for shareholders. Financial position As of May 29, 2025, the |
|
| May 30, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-284350 PROSPECTUS SUPPLEMENT No. 3 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 341,352,000,000 Ordinary Shares Representing 34,135,200 American Depositary Shares This prospectus supplement No. 3 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amen |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Address o |
|
| May 23, 2025 |
Exhibit 99.4 Proof 6 20-May-25 FOR AGAINST WITHHELD FOR AGAINST WITHHELD Res 1. Res 5. Res 2. Res 6. Res 3. Res 7. Res 4. BIODEXA PHARMACEUTICALS PLC TO THE REGISTERED HOLDERS OF AMERICAN DEPOSITARY RECEIPTS ("ADRs") REPRESENTING ORDINARY SHARES OF BIODEXA PHARMACEUTICALS PLC Sign below Date: Please sign this Voting Instruction Card exactly as your name(s) appear(s) on the face of this card and on |
|
| May 23, 2025 |
Exhibit 99.3 If you are planning to attend the Annual General Meeting, please tick the following box:Ñ>123|Ó>123-0Ordinary ResolutionsFORM OF PROXYBiodexa Pharmaceuticals PLC(a company incorporated in England and Wales under the Companies Act 2006 with company number 09216368)I?We being (a) member(s) of the Company and entitled to vote at the AnnualGeneral Meeting, hereby appoint(Please only compl |
|
| May 23, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 2 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 2,486,190,000 Ordinary Shares Representing 248,619 American Depositary Shares This prospectus supplement No. 2 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| May 23, 2025 |
Exhibit 99.2 NOTICE OF ANNUAL GENERAL MEETING BIODEXA PHARMACEUTICALS PLC (Incorporated and registered in England and Wales with registered no. 09216368) Notice is hereby given that an Annual General Meeting (“AGM”) of the members of Biodexa Pharmaceuticals PLC (the “Company”) will be held at 1 Caspian Point, Caspian Way, Cardiff, Wales, CF10 4DQ on 26 June 2025 at 1:00 p.m. to consider and, if th |
|
| May 23, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 2 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 4,349,102,800 Ordinary Shares Representing 434,901 American Depositary Shares This prospectus supplement No. 2 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| May 23, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-284350 PROSPECTUS SUPPLEMENT No. 2 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 341,352,000,000 Ordinary Shares Representing 34,135,200 American Depositary Shares This prospectus supplement No. 2 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amen |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of pri |
|
| May 22, 2025 |
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Exhibit 99.2 May 22, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company’s offices, 1 Caspian Point, Caspian W |
|
| May 22, 2025 |
Exhibit 99.1 NOTICE OF GENERAL MEETING BIODEXA PHARMACEUTICALS PLC (Incorporated and registered in England and Wales with registered no. 09216368) Notice is hereby given that a general meeting (“GM”) of the members of Biodexa Pharmaceuticals PLC (the “Company”) will be held at 1 Caspian Point, Caspian Way, Cardiff, Wales, CF10 4DQ on 11 June 2025 at 1:00 p.m. to consider and, if thought fit, pass |
|
| May 22, 2025 |
6-K 1 z5212516k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kin |
|
| May 22, 2025 |
EXHIBIT 99.1 Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M May 22, 2025 Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M Biod |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Address o |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of pri |
|
| May 15, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 1 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 2,486,190,000 Ordinary Shares Representing 248,619 American Depositary Shares This prospectus supplement No. 1 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| May 15, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 1 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 4,349,102,800 Ordinary Shares Representing 434,901 American Depositary Shares This prospectus supplement No. 1 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amended, |
|
| May 15, 2025 |
Annex A – Representations and Warranties Exhibit 10.1 May 15, 2025 [Name and address of warrant holder] Re: Reprice of Warrants To Whom It May Concern: Biodexa Pharmaceuticals PLC, a public limited company organized under the laws of England and Wales (the “Company”), is pleased to offer to you the opportunity to exercise the warrants set forth on your signature page attached hereto (the “Warrants”) and held by you (the “Holder”). The or |
|
| May 15, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-284350 PROSPECTUS SUPPLEMENT No. 1 (To the Prospectus dated May 9, 2025) BIODEXA PHARMACEUTICALS PLC 341,352,000,000 Ordinary Shares Representing 34,135,200 American Depositary Shares This prospectus supplement No. 1 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, as amen |
|
| May 12, 2025 |
341,352,000,000 Ordinary Shares Representing 34,135,200 American Depositary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-284350 PROSPECTUS 341,352,000,000 Ordinary Shares Representing 34,135,200 American Depositary Shares This prospectus relates to the potential offer and sale from time to time by C/M Capital Master Fund, LP, or the Selling Shareholder, of up to 341,352,000,000 of our ordinary shares, nominal value £0.00005 per share, or Ordinary Shares, represen |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Address o |
|
| May 12, 2025 |
2,486,190,000 Ordinary Shares Representing 248,619 American Depositary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-279994 PROSPECTUS 2,486,190,000 Ordinary Shares Representing 248,619 American Depositary Shares This prospectus relates to the resale from time to time, by the selling shareholders identified in this prospectus, of up to an aggregate of 2,486,190,000 ordinary shares, nominal value £0.00005 per share, or Ordinary Shares, of Biodexa Pharmaceutica |
|
| May 12, 2025 |
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP EXHIBIT 99.1 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019 Company nears start of Registrational Phase 3 study targeted at an addressable market of $7.3Bn Biodexa Pharmaceu |
|
| May 12, 2025 |
4,349,010,000 Ordinary Shares Representing 434,901 American Depositary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-281489 PROSPECTUS 4,349,010,000 Ordinary Shares Representing 434,901 American Depositary Shares This prospectus relates to the resale from time to time, by the selling shareholders identified in this prospectus, of up to an aggregate of 4,349,010,000 ordinary shares, nominal value £0.00005 per share, or Ordinary Shares, of Biodexa Pharmaceutica |
|
| May 8, 2025 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 8, 2025 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 8, 2025 Registration No. |
|
| May 8, 2025 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 8, 2025 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 8, 2025 Registration No. |
|
| May 2, 2025 |
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Exhibit 99.1 May 2, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces that at its General Meeting held at 1.00pm BST today, ordinary resolutions 1 and 2 were passed |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of pri |
|
| May 1, 2025 |
Confidential Treatment Requested by Biodexa Pharmaceuticals PLC Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the U.S. Securities and Exchange Commission on May 1, 2025. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SEC |
|
| April 29, 2025 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 29, 2025 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 29, 2025 Registration No. |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Address |
|
| April 17, 2025 |
Exhibit 99.2 NOTICE OF GENERAL MEETING BIODEXA PHARMACEUTICALS PLC (Incorporated and registered in England and Wales with registered no. 09216368) Notice is hereby given that a general meeting (“GM”) of the members of Biodexa Pharmaceuticals PLC (the “Company”) will be held at 1 Caspian Point, Caspian Way, Cardiff, Wales, CF10 4DQ on 2 May 2025 at 1:00 p.m. to consider and, if thought fit, pass th |
|
| April 17, 2025 |
EXHIBIT 99.1 Notice of General Meeting April 17, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company’s offices |
|
| April 11, 2025 |
Exhibit 99.1 April 11, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, an |
|
| April 11, 2025 |
Exhibit 15.1 The Directors Biodexa Pharmaceuticals plc 1 Caspian Point Caspian Way Cardiff Wales CF10 4DQ DDI: +44 (0)20 7516 2200 Email: [email protected] Date: 10 April 2025 Consent of Independent Registered Public Accounting Firm – Exhibit 15.1 Dear Sir / Madam We consent to the inclusion of our audit report dated April 10, 2025 in the Annual Report on Form 20-F on the consolidated financial |
|
| April 11, 2025 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 2.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of the securities registered under Section 12 of the Securities Exchange Act of 1934, as amended of Biodexa Pharmaceutucals PLC (“Biodexa,” “we,” “us,” “our” or the “Company”) is a summary of the rights of our issued share capital and certain provisions of our articles of association. Th |
|
| April 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 11, 2025 |
DATED 14 March 2025 BIODEXA PHARMACEUTICALS PLC INSIDER TRADING/SHARE DEALING CODE Exhibit 11.1 DATED 14 March 2025 BIODEXA PHARMACEUTICALS PLC INSIDER TRADING/SHARE DEALING CODE BIODEXA PHARMACEUTICALS PLC COMPANY INSIDER TRADING SHARE DEALING CODE (the Code) 1. INTRODUCTION 1.1 Laws of the United Kingdom, the United States and other territories in which the Company operates prohibit dealing in Securities and certain other actions based on inside information. 1.2 If you have an |
|
| April 11, 2025 |
Exhibit 13.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report on Form 20-F of Biodexa Pharmaceuticals PLC (the “Company”) for the year ended December 31, 2024, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Stephen Stamp, |
|
| April 11, 2025 |
6-K 1 z4102506k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United K |
|
| April 11, 2025 |
Exhibit 15.2 30 Old Bailey London EC4M 7AU Tel: +44 (0)20 7063 4000 forvismazars.com/uk Consent of Independent Registered Public Accounting Firm The Board of Directors of Biodexa Pharmaceuticals PLC, We hereby consent to the incorporation by reference in this Form 20-F (to be filed on or about April 11, 2025) of our audit report dated April 18, 2024 with respect to the consolidated balance sheets |
|
| April 11, 2025 |
Biodexa Pharmaceuticals PLC Promissory Note Exhibit 4.15 THIS HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THIS NOTE HAS BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PU |
|
| April 11, 2025 |
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 12.1 Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Stephen Stamp, certify that: 1. I have reviewed this annual report on Form 20-F of Biodexa Pharmaceuticals PLC (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the c |
|
| March 10, 2025 |
EXHIBIT 99.1 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP March 10, 2025 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S. Phase 3 substantially funded by $17.0 million CPRIT grant and $8.5 million |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Address |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Address |
|
| March 6, 2025 |
EXHIBIT 99.1 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase 3 registrational study of eRapa in Familial Adenomatous Polyposi |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Addr |
|
| February 24, 2025 |
EXHIBIT 99.1 Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use February 24, 2025 Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use Biodexa plans to initiate a Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Biodexa Pharmaceuticals PLC |
|
| February 18, 2025 |
EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The unders |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Addr |
|
| February 13, 2025 |
Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 EXHIBIT 99.1 Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 February 13, 2025 Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025 Biodexa Pharmaceuticals PLC invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth |
|
| February 10, 2025 |
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis EXHIBIT 99.1 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal of the colon and/or rectum Biodexa Pharmaceuticals PLC (“Biodexa” or “the Comp |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Addr |
|
| January 28, 2025 |
358,750,000,000 Ordinary Shares Representing 35,875,000 American Depositary Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-284350 PROSPECTUS 358,750,000,000 Ordinary Shares Representing 35,875,000 American Depositary Shares This prospectus relates to the potential offer and sale from time to time by C/M Capital Master Fund, LP, or the Selling Shareholder, of up to 358,750,000,000 of our ordinary shares, nominal value £0.00005 per share, or Ordinary Shares, represen |
|
| January 23, 2025 |
January 23, 2025 Stephen Stamp Chief Executive Officer Biodexa Pharmaceuticals PLC 1 Caspian Point Caspian Way Cardiff, CF10 4DQ, United Kingdom Re: Biodexa Pharmaceuticals PLC Registration Statement on Form F-1 Filed January 17, 2025 File No. |
|
| January 23, 2025 |
Biodexa Pharmaceuticals PLC 1 Caspian Point Caspian Way Cardiff, CF10 4DQ United Kingdom Biodexa Pharmaceuticals PLC 1 Caspian Point Caspian Way Cardiff, CF10 4DQ United Kingdom January 23, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporate Finance 100 F Street, N. |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Addre |
|
| January 22, 2025 |
Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer EXHIBIT 99.1 Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatm |
|
| January 21, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-272693 PROSPECTUS SUPPLEMENT No. 19 (to Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 115,102,400 Ordinary Shares Representing 287,756 American Depositary Shares This prospectus supplement No. 19 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 1 to Registration State |
|
| January 21, 2025 |
BIODEXA PHARMACEUTICALS PLC 8,203,200 Ordinary Shares Representing 20,508 American Depositary Shares Filed pursuant to Rule 424(b)(3) Registration No.: 333-270353 PROSPECTUS SUPPLEMENT No. 19 (To the Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 8,203,200 Ordinary Shares Representing 20,508 American Depositary Shares This prospectus supplement No. 19 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 3 to Registration Stat |
|
| January 21, 2025 |
BIODEXA PHARMACEUTICALS PLC 492,400 Ordinary Shares Representing 1,230 American Depositary Shares Filed pursuant to Rule 424(b)(3) Registration No.: 333-240984 PROSPECTUS SUPPLEMENT No. 19 (to Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 492,400 Ordinary Shares Representing 1,230 American Depositary Shares This prospectus supplement No. 19 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 4 to Registration Statement o |
|
| January 21, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 8 (To the Prospectus dated August 12, 2024) BIODEXA PHARMACEUTICALS PLC 4,349,102,800 Ordinary Shares Representing 10,872,757 American Depositary Shares This prospectus supplement No. 8 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, effec |
|
| January 21, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-278040 PROSPECTUS SUPPLEMENT No. 12 (To the Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 1,192,023,200 Ordinary Shares Representing 2,980,058 American Depositary Shares This prospectus supplement No. 12 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 1 to Registrati |
|
| January 21, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-274895 PROSPECTUS SUPPLEMENT No. 13 (To the Prospectus dated December 18, 2023) BIODEXA PHARMACEUTICALS PLC 697,614 Class A Units consisting of 697,614 American Depositary Shares Representing Ordinary Shares, 697,614 Series E Warrants to purchase 697,614 American Depositary Shares Representing Ordinary shares and 697,614 Series F Warrants to p |
|
| January 21, 2025 |
424B3 1 b424b3ps10279994.htm PROSPECTUS SUPPLEMENT NO. 10 Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 10 (To the Prospectus dated June 14, 2024) BIODEXA PHARMACEUTICALS PLC 2,486,270,400 Ordinary Shares Representing 6,215,676 American Depositary Shares This prospectus supplement No. 10 (the “Prospectus Supplement”) amends and supplements our prospectus c |
|
| January 17, 2025 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 17, 2025 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JANUARY 17, 2025 Registration No. |
|
| January 17, 2025 |
Exhibit 21.1 Subsidiaries Country of Incorporation Voting Interest Subsidiaries of Biodexa Pharmaceuticals PLC Biodexa Pharmaceuticals (Wales) Limited England and Wales 100% Biodexa Ltd England and Wales 100% Haaland UK Limited (2) England and Wales 100% Subsidiaries of Biodexa Ltd Pharmida AG (2) Switzerland 100% (1) Dormant entities. |
|
| January 17, 2025 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following describes our issued share capital, summarizes the material provisions of our articles of association and highlights certain differences in corporate law in the United Kingdom and the United States. Please note that this summary is not intended to be exhaustive. For further information please refer |
|
| January 17, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 17, 2025 (the “Execution Date”), by and between BIODEXA PHARMACEUTICALS PLC, a company incorporated under the laws of England and Wales (the “Company”), and C/M CAPITAL MASTER FUND, LP, a Delaware limited partnership (the “Investor”). WHEREAS: Subject to the terms and conditions set |
|
| January 17, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-1 Biodexa Pharmaceuticals PLC Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Shares, nominal value £0. |
|
| January 17, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of January 17, 2025 (the “Execution Date”), is entered into by and between BIODEXA PHARMACEUTICALS PLC, a company incorporated under the laws of England and Wales (the “Company”), and C/M CAPITAL MASTER FUND, LP, a Delaware limited partnership (together with its permitted assigns, the “Buyer” |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of |
|
| January 8, 2025 |
BIODEXA PHARMACEUTICALS PLC 492,400 Ordinary Shares Representing 1,230 American Depositary Shares Filed pursuant to Rule 424(b)(3) Registration No.: 333-240984 PROSPECTUS SUPPLEMENT No. 18 (to Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 492,400 Ordinary Shares Representing 1,230 American Depositary Shares This prospectus supplement No. 18 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 4 to Registration Statement o |
|
| January 8, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-274895 PROSPECTUS SUPPLEMENT No. 12 (To the Prospectus dated December 18, 2023) BIODEXA PHARMACEUTICALS PLC 697,614 Class A Units consisting of 697,614 American Depositary Shares Representing Ordinary Shares, 697,614 Series E Warrants to purchase 697,614 American Depositary Shares Representing Ordinary shares and 697,614 Series F Warrants to p |
|
| January 8, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-272693 PROSPECTUS SUPPLEMENT No. 18 (to Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 115,102,400 Ordinary Shares Representing 287,756 American Depositary Shares This prospectus supplement No. 18 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 1 to Registration State |
|
| January 8, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 7 (To the Prospectus dated August 12, 2024) BIODEXA PHARMACEUTICALS PLC 4,349,102,800 Ordinary Shares Representing 10,872,757 American Depositary Shares This prospectus supplement No. 7 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, effec |
|
| January 8, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-278040 PROSPECTUS SUPPLEMENT No. 11 (To the Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 1,192,023,200 Ordinary Shares Representing 2,980,058 American Depositary Shares This prospectus supplement No. 11 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 1 to Registrati |
|
| January 8, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 9 (To the Prospectus dated June 14, 2024) BIODEXA PHARMACEUTICALS PLC 2,486,270,400 Ordinary Shares Representing 6,215,676 American Depositary Shares This prospectus supplement No. 9 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, effectiv |
|
| January 8, 2025 |
BIODEXA PHARMACEUTICALS PLC 8,203,200 Ordinary Shares Representing 20,508 American Depositary Shares Filed pursuant to Rule 424(b)(3) Registration No.: 333-270353 PROSPECTUS SUPPLEMENT No. 18 (To the Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 8,203,200 Ordinary Shares Representing 20,508 American Depositary Shares This prospectus supplement No. 18 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 3 to Registration Stat |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address o |
|
| December 27, 2024 |
Exhibit 1.1 BIODEXA PHARMACEUTICALS PLC (registered number 09216368) ARTICLES OF ASSOCIATION TWM/031674.0002 8 Clifford Street London W1S 2LQ www.brownrudnick.com T: 020 7851 6000 F: 020 7851 6100 Table of Contents PRELIMINARY 1 1 DEFINITIONS 1 2 LIABILITY OF MEMBERS 5 3 FORM OF RESOLUTION 5 4 EXCLUSION OF MODEL ARTICLES (AND ANY OTHER PRESCRIBED REGULATIONS) 5 5 REGISTERED OFFICE 5 SHARE CAPITAL |
|
| December 27, 2024 |
Biodexa Pharmaceuticals PLC Promissory Note Exhibit 10.1 THIS HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE. THIS NOTE HAS BEEN SOLD IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PU |
|
| December 4, 2024 |
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Exhibit 99.1 November 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces, announces that at its General Meeting held earlier today, b |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address o |
|
| November 20, 2024 |
SC 13G/A 1 ea0221977-13ga1briobio.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No. 1) UNDER THE SECURITIES EXCHANGE ACT OF 1934* BIODEXA PHARMACEUTICALS PLC (Name of Issuer) AMERICAN DEPOSITORY SHARES** (Title of Class of Securities) 59564R708*** (CUSIP Number) November 14, 2024 (Date of Event Which Requires Fil |
|
| November 14, 2024 |
SC 13G/A 1 c110565sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Biodexa Pharmaceuticals PLC (Name of Issuer) American Depositary Shares, each representing 400 Ordinary Shares (Title of Clas |
|
| November 12, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 6 (To the Prospectus dated August 12, 2024) BIODEXA PHARMACEUTICALS PLC 4,349,102,800 Ordinary Shares Representing 10,872,757 American Depositary Shares This prospectus supplement No. 6 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, effec |
|
| November 12, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-272693 PROSPECTUS SUPPLEMENT No. 17 (to Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 115,102,400 Ordinary Shares Representing 287,756 American Depositary Shares This prospectus supplement No. 17 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 1 to Registration State |
|
| November 12, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-274895 PROSPECTUS SUPPLEMENT No. 11 (To the Prospectus dated December 18, 2023) BIODEXA PHARMACEUTICALS PLC 697,614 Class A Units consisting of 697,614 American Depositary Shares Representing Ordinary Shares, 697,614 Series E Warrants to purchase 697,614 American Depositary Shares Representing Ordinary shares and 697,614 Series F Warrants to p |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address o |
|
| November 12, 2024 |
BIODEXA PHARMACEUTICALS PLC 492,400 Ordinary Shares Representing 1,230 American Depositary Shares Filed pursuant to Rule 424(b)(3) Registration No.: 333-240984 PROSPECTUS SUPPLEMENT No. 17 (to Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 492,400 Ordinary Shares Representing 1,230 American Depositary Shares This prospectus supplement No. 17 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 4 to Registration Statement o |
|
| November 12, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-278040 PROSPECTUS SUPPLEMENT No. 10 (To the Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 1,192,023,200 Ordinary Shares Representing 2,980,058 American Depositary Shares This prospectus supplement No. 10 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 1 to Registrati |
|
| November 12, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 8 (To the Prospectus dated June 14, 2024) BIODEXA PHARMACEUTICALS PLC 2,486,270,400 Ordinary Shares Representing 6,215,676 American Depositary Shares This prospectus supplement No. 8 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, effectiv |
|
| November 12, 2024 |
SC 13G/A 1 sc13ga110022bdrx11122024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Biodexa Pharmaceuticals PLC (Name of Issuer) Ordinary Shares, Nominal Value $.001 per share (Title |
|
| November 12, 2024 |
Exhibit 99.1 November 12, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces that the Company has been formally notified that the Nasdaq Hea |
|
| November 12, 2024 |
BIODEXA PHARMACEUTICALS PLC 8,203,200 Ordinary Shares Representing 20,508 American Depositary Shares Filed pursuant to Rule 424(b)(3) Registration No.: 333-270353 PROSPECTUS SUPPLEMENT No. 17 (To the Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 8,203,200 Ordinary Shares Representing 20,508 American Depositary Shares This prospectus supplement No. 17 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 3 to Registration Stat |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Addr |
|
| November 7, 2024 |
SC 13G/A 1 p24-3286sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Biodexa Pharmaceuticals PLC (Name of Issuer) Ordinary shares, nominal value £0.001 per share (Title of Class of Securities) 59564R708** (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| November 7, 2024 |
EXHIBIT 99.1 Notice of General Meeting November 7, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company’s offic |
|
| November 5, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-274895 PROSPECTUS SUPPLEMENT No. 10 (To the Prospectus dated December 18, 2023) BIODEXA PHARMACEUTICALS PLC 697,614 Class A Units consisting of 697,614 American Depositary Shares Representing Ordinary Shares, 697,614 Series E Warrants to purchase 697,614 American Depositary Shares Representing Ordinary shares and 697,614 Series F Warrants to p |
|
| November 5, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 5 (To the Prospectus dated August 12, 2024) BIODEXA PHARMACEUTICALS PLC 4,349,102,800 Ordinary Shares Representing 10,872,757 American Depositary Shares This prospectus supplement No. 5 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, effec |
|
| November 5, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-272693 PROSPECTUS SUPPLEMENT No. 16 (to Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 115,102,400 Ordinary Shares Representing 287,756 American Depositary Shares This prospectus supplement No. 16 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 1 to Registration State |
|
| November 5, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 7 (To the Prospectus dated June 14, 2024) BIODEXA PHARMACEUTICALS PLC 2,486,270,400 Ordinary Shares Representing 6,215,676 American Depositary Shares This prospectus supplement No. 7 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, effectiv |
|
| November 5, 2024 |
BIODEXA PHARMACEUTICALS PLC 492,400 Ordinary Shares Representing 1,230 American Depositary Shares Filed pursuant to Rule 424(b)(3) Registration No.: 333-240984 PROSPECTUS SUPPLEMENT No. 16 (to Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 492,400 Ordinary Shares Representing 1,230 American Depositary Shares This prospectus supplement No. 16 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 4 to Registration Statement o |
|
| November 5, 2024 |
BIODEXA PHARMACEUTICALS PLC 8,203,200 Ordinary Shares Representing 20,508 American Depositary Shares Filed pursuant to Rule 424(b)(3) Registration No.: 333-270353 PROSPECTUS SUPPLEMENT No. 16 (To the Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 8,203,200 Ordinary Shares Representing 20,508 American Depositary Shares This prospectus supplement No. 16 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 3 to Registration Stat |
|
| November 5, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-278040 PROSPECTUS SUPPLEMENT No. 9 (To the Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 1,192,023,200 Ordinary Shares Representing 2,980,058 American Depositary Shares This prospectus supplement No. 9 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 1 to Registration |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address o |
|
| November 1, 2024 |
Securities and Exchange Commission Exhibit 16.1 30 Old Bailey London EC4M 7AU Tel: +44 (0)20 7063 4000 forvismazars.com/uk Private & Confidential Securities and Exchange Commission 100 F Street NE Washington D.C. 20549 United States of America Date: 1 November 2024 Ladies and Gentlemen, We have been furnished with a copy of the form 6-K to be filed by our former client, Biodexa Pharmaceuticals plc, to satisfy its reporting obligati |
|
| October 16, 2024 |
BIODEXA PHARMACEUTICALS PLC 492,400 Ordinary Shares Representing 1,230 American Depositary Shares Filed pursuant to Rule 424(b)(3) Registration No.: 333-240984 PROSPECTUS SUPPLEMENT No. 15 (to Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 492,400 Ordinary Shares Representing 1,230 American Depositary Shares This prospectus supplement No. 15 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 4 to Registration Statement o |
|
| October 16, 2024 |
BIODEXA PHARMACEUTICALS PLC 8,203,200 Ordinary Shares Representing 20,508 American Depositary Shares Filed pursuant to Rule 424(b)(3) Registration No.: 333-270353 PROSPECTUS SUPPLEMENT No. 15 (To the Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 8,203,200 Ordinary Shares Representing 20,508 American Depositary Shares This prospectus supplement No. 15 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 3 to Registration Stat |
|
| October 16, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-272693 PROSPECTUS SUPPLEMENT No. 15 (to Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 115,102,400 Ordinary Shares Representing 287,756 American Depositary Shares This prospectus supplement No. 15 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 1 to Registration State |
|
| October 16, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-274895 PROSPECTUS SUPPLEMENT No. 9 (To the Prospectus dated December 18, 2023) BIODEXA PHARMACEUTICALS PLC 697,614 Class A Units consisting of 697,614 American Depositary Shares Representing Ordinary Shares, 697,614 Series E Warrants to purchase 697,614 American Depositary Shares Representing Ordinary shares and 697,614 Series F Warrants to pu |
|
| October 16, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-278040 PROSPECTUS SUPPLEMENT No. 8 (To the Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 1,192,023,200 Ordinary Shares Representing 2,980,058 American Depositary Shares This prospectus supplement No. 8 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 1 to Registration |
|
| October 16, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-279994 PROSPECTUS SUPPLEMENT No. 6 (To the Prospectus dated June 14, 2024) BIODEXA PHARMACEUTICALS PLC 2,486,270,400 Ordinary Shares Representing 6,215,676 American Depositary Shares This prospectus supplement No. 6 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, effectiv |
|
| October 16, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-281489 PROSPECTUS SUPPLEMENT No. 4 (To the Prospectus dated August 12, 2024) BIODEXA PHARMACEUTICALS PLC 4,349,102,800 Ordinary Shares Representing 10,872,757 American Depositary Shares This prospectus supplement No. 4 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Registration Statement on Form F-1, effec |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of |
|
| October 15, 2024 |
Biodexa Announces Successful Appeal of Nasdaq Delisting Exhibit 99.1 October 15, 2024 Biodexa Announces Successful Appeal of Nasdaq Delisting Biodexa Pharmaceuticals PLC. (the “Company”) (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced today that a Nasdaq Hearings Panel (the “Panel”) has granted the Company’s req |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant's name into English) 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (Addre |
|
| October 4, 2024 |
EXHIBIT 99.1 Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma October 4, 2024 Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma Cohort A Data on Overall Survival Compare Favorably with Published Survival Rates Results Build on MTX110’s Performance in Two Phase 1 |
|
| September 27, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No.: 333-272693 PROSPECTUS SUPPLEMENT No. 14 (to Prospectus dated May 2, 2024) BIODEXA PHARMACEUTICALS PLC 115,102,400 Ordinary Shares Representing 287,756 American Depositary Shares This prospectus supplement No. 14 (the “Prospectus Supplement”) amends and supplements our prospectus contained in our Post-Effective Amendment No. 1 to Registration State |
